Skip to main content

Table 4 Risk factors for 28-day mortality among 36 patients infected by tigecycline non-susecptible K. pneumoniae bacteremia

From: Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in Taiwan

 

Survivors (n = 22), n (%)

Non-survivors (n = 14), n (%)

p

Adjustedpa

Age (years, median, IQR)

76.5, 69.3–84.3

71, 60.3–79

0.175

 

Male sex

17 (77.3)

10 (71.4)

0.988

 

Underlying disease

    

 Immunosuppressionb

5 (22.7)

4 (28.6)

0.988

 

 Diabetes mellitus

9 (40.9)

9 (64.3)

0.305

 

 Chronic obstructive lung disease

2 (9.1)

3 (21.4)

0.574

 

 Hemodialysis

5 (22.7)

6 (42.9)

0.364

 

 Malignancy

7 (31.8)

7 (50)

0.458

 

 Liver cirrhosis

2 ( 9.1)

1 (7.1)

1.000

 

 Cerebral vascular disease

6 (27.3)

4 (28.6)

1.000

 

 Charlson comorbidity score (median, IQR)

3, 2–5

4, 3–8.3

0.171

 

Pitt bacteremia score (mean ± SD)

3.3 ± 3.1

5.9 ± 3.7

0.037

0.847

APACHE II score (mean ± SD)

20.1 ± 0.6

27.6 ± 11.0

0.016

0.958

Acquired after ICU >48 h

3 (13.6)

11 (78.6)

<0.001

0.021

Infection sources and clinical syndrome

    

 Pneumonia

3 (13.6)

7 (50)

0.047

0.569

 Intra-abdominal infection other than biliary-tract infection

2 (9.1)

3 (21.4)

0.574

 

 Biliary-tract infection

7 (31.8)

0 (0)

  

 Unknown primary focus

8 (36.4)

2 (14.3)

0.289

 

Presentation with septic shock

9 (40.9)

10 (71.4)

0.147

 

Appropriate antibiotic treatment

12 (54.6)

6 (42.9)

0.733

 

Ertapenem non-susceptibility

6 (27.3)

2 (14.3)

0.628

 

Tigecycline MIC >4 μg/mL

10 (45.5)

8 (57.1)

0.733

 

Tigecycline MIC >6 μg/mL

4 (18.2)

6 (42.9)

0.220

 

ESBL-producing strain

10 (45.5)

8 (57.1)

0.733

 
  1. IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.
  2. aAll factors with p < 0.1 in univariate analyses were included in the exact logistic regression.
  3. bImmunosuppression includes patients who underwent solid-organ transplantation, corticosteroid therapy, and immunosuppression therapy.